BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 3937269)

  • 1. Postoperative changes in the plasmatic levels of tissue-type plasminogen activator and its fast-acting inhibitor--relationship to deep vein thrombosis and influence of prophylaxis.
    Páramo JA; Alfaro MJ; Rocha E
    Thromb Haemost; 1985 Oct; 54(3):713-6. PubMed ID: 3937269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative identification of patients at high risk of deep venous thrombosis despite prophylaxis in total hip replacement.
    Rocha E; Alfaro MJ; Páramo JA; Cañadell JM
    Thromb Haemost; 1988 Feb; 59(1):93-5. PubMed ID: 3363536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of oral stanozolol used in the prevention of postoperative deep vein thrombosis on fibrinolytic activity.
    Sue-Ling HM; Davies JA; Prentice CR; Verheijen JH; Kluft C
    Thromb Haemost; 1985 Feb; 53(1):141-2. PubMed ID: 3873118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombosis after hip replacement. Relationship to the fibrinolytic system.
    Eriksson BI; Eriksson E; Gyzander E; Teger-Nilsson AC; Risberg B
    Acta Orthop Scand; 1989 Apr; 60(2):159-63. PubMed ID: 2471386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis.
    Juhan-Vague I; Valadier J; Alessi MC; Aillaud MF; Ansaldi J; Philip-Joet C; Holvoet P; Serradimigni A; Collen D
    Thromb Haemost; 1987 Feb; 57(1):67-72. PubMed ID: 3109059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinolytic parameters in patients undergoing total hip replacement: relationship with the development of asymptomatic deep vein thrombosis and diagnostic usefulness of venous occlusion.
    Trotti R; Siragusa S; Rondanelli M; Chezzi L; Citterio A; Melzi d'Eril GV; Piovella F
    Haematologica; 1997; 82(2):178-81. PubMed ID: 9175322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma].
    Iwan-Zietek I; Zietek Z; Kotschy M; Rość D; Tyloch F
    Pol Tyg Lek; 1996 Feb; 51(6-9):91-3. PubMed ID: 8756741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal and hepatic handling of endogenous tissue-type plasminogen activator (t-PA) and its inhibitor in man.
    Brommer EJ; Derkx FH; Schalekamp MA; Dooijewaard G; vd Klaauw MM
    Thromb Haemost; 1988 Jun; 59(3):404-11. PubMed ID: 3142078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1).
    Kluft C; Jie AF; Rijken DC; Verheijen JH
    Thromb Haemost; 1988 Apr; 59(2):329-32. PubMed ID: 3133814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the medical treatment of deep vein thrombosis.
    Schulman S
    Acta Med Scand Suppl; 1985; 704():1-68. PubMed ID: 3913282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma fibrinolytic activity in patients undergoing major abdominal surgery.
    Mellbring G; Dahlgren S; Wiman B
    Acta Chir Scand; 1985; 151(2):109-14. PubMed ID: 3873768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrinolytic activity in plasma after gynecological and urological surgery.
    Aranda A; Páramo JA; Rocha E
    Haemostasis; 1988; 18(2):129-34. PubMed ID: 3137141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered fibrinolysis in DVT: influence of site of sampling.
    Han P; Koay ES; Tsakok M; Aw TC; Wong LY; Pradhan M
    Thromb Haemost; 1988 Aug; 60(1):50-3. PubMed ID: 3142091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diurnal variation of the fibrinolytic system.
    Grimaudo V; Hauert J; Bachmann F; Kruithof EK
    Thromb Haemost; 1988 Jun; 59(3):495-9. PubMed ID: 3142085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue type plasminogen activator (t-PA) activity and inhibits venous thrombosis.
    van Giezen JJ; Boon GI; Jansen JW; Bouma BN
    Thromb Haemost; 1993 Apr; 69(4):381-6. PubMed ID: 8497851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective double-arm study of fibrinolysis in surgical patients.
    Kosir MA; Schmittinger L; Barno-Winarski L; Duddella P; Pone M; Perales A; Lange P; Brish LK; McGee K; Beleski K; Pawlak J; Mammen E; Sajahan NP; Kozol RA
    J Surg Res; 1998 Jan; 74(1):96-101. PubMed ID: 9536981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
    Johansson JO; Landin K; Johannsson G; Tengborn L; Bengtsson BA
    Thromb Haemost; 1996 Sep; 76(3):422-8. PubMed ID: 8883281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasminogen activator inhibitor (PA-inhibitor) activity in the blood of patients with deep vein thrombosis.
    Paramo JA; de Boer A; Colucci M; Jonker JJ; Collen D
    Thromb Haemost; 1985 Oct; 54(3):725. PubMed ID: 3937271
    [No Abstract]   [Full Text] [Related]  

  • 20. A dynamic test to investigate potential tissue plasminogen activator activity. Comparison of deamino-8-D-argininevasopressin with venous occlusion in normal subjects and patients.
    Sultan Y; Harris A; Strauch G; Venot A; De Lauture D
    J Lab Clin Med; 1988 Jun; 111(6):645-53. PubMed ID: 3131470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.